Finnish Biobanks (FINBB) Partners with TriNetX to Increase Clinical and Biomedical Trials in Finland

CAMBRIDGE, Mass., June 14, 2022 /PRNewswire/ — TriNetX, LLC, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Finnish Biobanks (FINBB), a cooperative owned by the six largest hospital districts and universities in Finland and the Finnish Institute for Health and Welfare, joined the TriNetX network. The aim of the collaboration is to connect leading Finnish healthcare organizations to the national FINBB collaboration known as the Fingenious® Service Network, and to attract more research projects as well as increase the number of clinical trials in Finland.

“The volume of clinical trials conducted in Finland has declined over the past decade, which may reduce opportunities for clinicians to learn more about innovative treatment options, medications, and benefits for their patients,” said Marco Hautalahti, CEO of FINBB. “We believe that collaborating with the TriNetX network will help us reverse this trend in Finland for the benefit of patients suffering from different types of devastating diseases. This partnership is a significant opportunity for the entire Finnish healthcare ecosystem.”

“TriNetX is the global leader in this field and is uniquely positioned to efficiently connect R&D-focused companies to Finnish healthcare organizations participating in the Fingenious® collaboration,” Hautalahti continued. “TriNetX has a proven track record of implementation excellence and global reach. At FINBB, together with our Finnish network members, we have researched the platform and found it to be comprehensive and user-friendly.”

TriNetX is the largest and fastest growing collaborative research network, representing healthcare organizations and health data partners around the world. TriNetX has presented thousands of clinical trial opportunities to healthcare organizations on its network and has been cited in hundreds of scientific and peer-reviewed publications.

“We are delighted to welcome FINBB to the TriNetX network,” said Steve Lethbridge, Senior Vice President, Global Healthcare Partnerships at TriNetX. “Finland is one of the most advanced countries in Europe in terms of the quantity and quality of real-world structured data. We look forward to helping FINBB increase its collaborative research capabilities with the global TriNetX community.”

About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life science companies conducting real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHRs, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its global community to improve protocol design, streamline trial operations, refine safety signals, and enrich the generation of real-world evidence. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.

About FINBB
The Fingenious® service is operated by the Finnish Biobank Cooperative (FINBB). FINBB’s mission is to improve the competitiveness of Finnish health and biomedical research by providing researchers with centralized access to the collections and services of Finnish biobanks and their reference organizations. The company’s model is value-based: data generated in scientific studies is fed back to biobanks for use in the further development of treatments. FINBB is a cooperative owned by the six largest hospital districts and universities in Finland, and the Finnish Institute for Health and Welfare (THL). www.finbb.fi, www.fingenious.fi, follow us on Twitter @Fingenious_FI.

Media Contacts

FINBB
Marco Hautalahti
(+358) 400-493 613
[email protected]

TriNetX, LLC
Bill Stetson
(857) 285-6038
[email protected]

Logo- https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

SOURCETriNetX

About Terry Gongora

Check Also

Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at the Precision Medicine World Conference

Title: Removing Barriers to Biomarker Testing Through Collaboration Time: Tuesday, June 28 at 9:00 a.m. …